NCT07428993
Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 25 words
- Start date changed from estimate of Sep 2026 to Aug 21, 2026
- Secondary endpoints: details revised at 2 of 3 entries
- Site details revised
- Notable Start date: Jun 2026 to Sep 2026
- Primary endpoint(s) modified
- Secondary endpoints revised (3)
- Study description revised
- Notable Recruitment opened
- Site contact updated
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Start date: Feb 2026 to Jun 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
All patients will receive standard of care chemotherapy, which is not considered part of protocol therapy. Eligible patients will undergo apheresis prior to standard local control surgery for CAR T cell manufacture and then resume standard therapy. In the absence of progressive disease, eligible patients with available SJCARB7H3-41BBL product will receive lymphodepletion chemotherapy (fludarabine/cyclophosphamide) after the completion of standard chemotherapy, followed by SJCARB7H3-41BBL infusion. Pulmonary metastasectomy will be performed as indicated according to the standard of care and will be timed after (Regimen A) or before (Regimen B) lymphodepletion and SJCARB7H3-41BBL infusion. Following successful clearance of either regimen A or, if necessary, regimen B, the efficacy cohort will be initiated.
Drugs: Cyclophosphamide, Fludarabine, Mesna
Procedures: Apheresis, SJCARB7H3_41BBL infusion
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States